甘李药业
(603087)
| 流通市值：254.54亿 | | | 总市值：284.78亿 |
| 流通股本：5.31亿 | | | 总股本：5.94亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 2,552,990,893.78 | 2,442,708,603.2 | 2,093,406,319.02 | 3,062,691,296.04 |
| 应收票据及应收账款 | 269,599,231.21 | 383,735,270.9 | 398,288,006.98 | 277,004,079.96 |
| 应收账款 | 269,599,231.21 | 383,735,270.9 | 398,288,006.98 | 277,004,079.96 |
| 应收款项融资 | 18,561,967.25 | 1,634,782.89 | 17,900,528.4 | 11,423,343.37 |
| 预付款项 | 59,366,039.72 | 40,979,491.54 | 36,306,664.98 | 42,575,151.02 |
| 其他应收款合计 | 3,602,947.45 | 3,491,907.62 | 3,859,363.88 | 21,065,314.16 |
| 应收股利 | - | - | - | 17,361,100 |
| 存货 | 932,042,171.36 | 860,506,306.14 | 858,848,392.87 | 749,457,462.42 |
| 其他流动资产 | 31,883,590.65 | 32,263,551.43 | 1,963,899.71 | 14,378,543.75 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 6,215,027,747.41 | 6,175,749,710.54 | 5,488,181,400.13 | 5,712,582,496.26 |
| 非流动资产: | | | | |
| 债权投资 | 307,122,916.67 | 304,658,333.33 | 302,166,666.67 | - |
| 其他非流动金融资产 | 30,000,000 | 30,000,000 | 30,000,000 | 30,000,000 |
| 固定资产 | 1,851,745,745.49 | 1,872,067,763.13 | 1,813,532,086.73 | 1,804,938,547.92 |
| 在建工程 | 2,024,005,518.27 | 2,006,961,148.27 | 1,894,127,467.15 | 1,894,471,040.63 |
| 使用权资产 | 4,475,734.51 | 6,592,364.52 | 9,160,983.53 | 9,953,333.19 |
| 无形资产 | 271,278,567.88 | 278,082,595.92 | 280,506,605.44 | 283,351,735.65 |
| 开发支出 | 818,633,186.96 | 813,105,292.99 | 795,570,714.94 | 788,779,209.56 |
| 长期待摊费用 | 8,426,265.99 | 8,868,054.7 | 9,312,158.66 | 9,755,476.18 |
| 递延所得税资产 | 152,239,174.14 | 168,953,020.84 | 109,451,926.06 | 114,193,038.65 |
| 其他非流动资产 | 36,999,556.26 | 49,985,187.56 | 93,027,565.3 | 81,118,551.95 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 5,504,926,666.17 | 5,539,273,761.26 | 5,336,856,174.48 | 5,016,560,933.73 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 11,719,954,413.58 | 11,715,023,471.8 | 10,825,037,574.61 | 10,729,143,429.99 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 107,433,009.23 | 105,541,739.99 | 89,744,391.36 | 97,858,933.74 |
| 应付账款 | 107,433,009.23 | 105,541,739.99 | 89,744,391.36 | 97,858,933.74 |
| 合同负债 | 32,639,152.15 | 52,991,852.39 | 47,599,346.55 | 58,273,953.62 |
| 应付职工薪酬 | 151,941,854.52 | 139,761,214.89 | 142,067,160.12 | 155,099,300.15 |
| 应交税费 | 10,206,577.59 | 16,910,777.27 | 22,102,737.34 | 15,525,909.43 |
| 其他应付款合计 | 377,540,224.77 | 454,009,437.8 | 400,708,144.18 | 439,667,831.37 |
| 一年内到期的非流动负债 | 2,292,334.37 | 3,958,443.73 | 15,275,760.16 | 12,957,297.19 |
| 其他流动负债 | 297,868.18 | 275,580.81 | 158,356.62 | 231,412.51 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 682,351,020.81 | 773,449,046.88 | 717,655,896.33 | 779,614,638.01 |
| 非流动负债: | | | | |
| 租赁负债 | 3,909,110.41 | 5,447,249.65 | 8,180,032.99 | 8,525,593.89 |
| 长期应付款 | 13,778,661.53 | 13,995,107.23 | 14,614,041.61 | 11,266,595.95 |
| 递延收益 | 177,324,731.68 | 179,625,640.4 | 182,698,431.05 | 185,036,736.97 |
| 递延所得税负债 | - | - | 11,445,496.57 | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 195,012,503.62 | 199,067,997.28 | 216,938,002.22 | 204,828,926.81 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 877,363,524.43 | 972,517,044.16 | 934,593,898.55 | 984,443,564.82 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 594,161,750 | 594,161,750 | 565,653,200 | 565,653,200 |
| 资本公积 | 3,354,945,052.71 | 3,350,753,839.87 | 2,600,461,124.09 | 2,586,117,853.99 |
| 减:库存股 | 71,364,020 | 71,364,020 | 71,364,020 | 71,364,020 |
| 其他综合收益 | 3,706,443.79 | 3,817,428.85 | 4,311,585.79 | 5,231,687.54 |
| 盈余公积 | 297,080,875 | 297,080,875 | 291,531,843.96 | 291,531,843.96 |
| 未分配利润 | 6,664,060,427.4 | 6,568,056,149.2 | 6,500,012,491.06 | 6,367,691,853.09 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 10,842,590,528.9 | 10,742,506,022.92 | 9,890,606,224.9 | 9,744,862,418.58 |
| 少数股东权益 | 360.25 | 404.72 | -162,548.84 | -162,553.41 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 10,842,590,889.15 | 10,742,506,427.64 | 9,890,443,676.06 | 9,744,699,865.17 |
| 负债和股东权益合计 | 11,719,954,413.58 | 11,715,023,471.8 | 10,825,037,574.61 | 10,729,143,429.99 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-31 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |